ArticleNeoplasia (New York, N.Y.)2026
Heterogeneous SPP1-expressing esophageal cancer cells license immunotherapy resistance by organizing an immunosuppressive niche.
Article in Neoplasia (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEsophageal squamous cell carcinoma (ESCC) remains a major cause of cancer-related mortality worldwide, with immunotherapy resistance representing a critical therapeutic challenge. This resistance is driven by profound tumor heterogeneity that fosters diverse immune evasion mechanisms, limiting the efficacy of current treatments. Thus, an urgent need exists to identify the key drivers within heterogeneous tumors that potentiate immunotherapeutic resistance.
methodsSingle-cell, spatial, and bulk transcriptomic data from multiple ESCC cohorts were integrated to map the cellular ecosystems and decipher the heterogeneity of immunotherapy-resistant tumors. Multi-cohort analyses were conducted to assess clinical relevance, and key findings were validated through targeted functional assays in vitro and in vivo.
resultsWe discovered a previously unrecognized secreted phosphoprotein 1 (SPP1)-expressing malignant epithelial subpopulation that is markedly enriched in non-responders, representing a critical component of tumor heterogeneity. Elevated SPP1 expression correlated with immunotherapy resistance and poorer survival across independent cohorts. Mechanistically, SPP1 promoted tumor proliferation and migration while upregulating PD-L1 via the mTORC1-STAT3 pathway, as revealed by our RNA-sequencing data. Furthermore, SPP1 induced CD8⁺ T cell exhaustion through SPP1-CD44 signaling, accompanied by CD44-dependent MAPK activation, and polarized macrophages toward an immunosuppressive phenotype via α5β1 integrin-dependent FAK-AKT-mTOR activation. Spatial transcriptomics validation demonstrated that SPP1⁺ cells shape immunosuppressive niches within the tumor microenvironment. Therapeutically, SPP1 blockade enhanced the antitumor effect of anti-PD-1 therapy to suppress tumor growth in vivo. To directly address tumor heterogeneity, we employed drug sensitivity profiling that nominated microtubule and kinase inhibitors as potent agents against SPP1⁺ cells, providing a strategy to target resistant subpopulations.
conclusionThis study establishes SPP1 as both a key driver of immunotherapy resistance in heterogeneous ESCC tumors and a promising therapeutic target for overcoming treatment failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.